MicroRNA‑1301‑3p promotes the progression of non‑small cell lung cancer by targeting Thy‑1 and predicts poor prognosis of patients

Xu,Ling; Ni,Na; Gao,Haiyang; Hu,Pengbo

doi:10.3892/ol.2021.12589

MicroRNA‑1301‑3p promotes the progression of non‑small cell lung cancer by targeting Thy‑1 and predicts poor prognosis of patients

Authors:
- Ling Xu
- Na Ni
- Haiyang Gao
- Pengbo Hu
View Affiliations

Affiliations: Department of Respiratory and Critical Care Medicine, Binzhou Medical University Hospital, Binzhou, Shandong 256600, P.R. China, Department of Clinical Medical Laboratory, Binzhou Medical University Hospital, Binzhou, Shandong 256600, P.R. China, Department of Emergency, Binzhou Medical University Hospital, Binzhou, Shandong 256600, P.R. China
Published online on: February 24, 2021 https://doi.org/10.3892/ol.2021.12589
Article Number: 327
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The role of microRNA (miR)‑1301‑3p has been investigated in breast cancer and colorectal cancer. Dysregulation of miR‑1301‑3p expression in non‑small cell lung cancer (NSCLC) is speculated to be associated with tumor progression, which was systemically investigated in the present study. Reverse transcription‑quantitative PCR analysis was performed to detect miR‑1301‑3p expression in 124 paired tissue samples and cultured cell lines. The results demonstrated that miR‑1301‑3p expression was regulated by transfection with miR‑1301‑3p mimic or inhibitor, and the proliferation, migration and invasion of the transfected cells were assessed via the Cell Counting Kit‑8 and Transwell assays. In addition, miR‑1301‑3p expression was significantly upregulated in NSCLC tissues and cells compared with normal tissues and normal cells, respectively. Notably, upregulated miR‑1301‑3p expression in NSCLC tissues was significantly associated with the TNM stage, lymph node metastasis and poor prognosis of patients with NSCLC. Furthermore, upregulated miR‑1301‑3p expression in NSCLC cells promoted cell proliferation, migration and invasion, the effects of which were reversed following miR‑1301‑3p knockdown. Thy‑1 was identified as a direct target of miR‑1301‑3p, which serves as a tumor promoter in the progression of NSCLC. Taken together, the results of the present study suggest that upregulated miR‑1301‑3p expression in NSCLC acts as an independent prognostic factor and a tumor promoter by targeting thy‑1, thus provides a potential therapeutic target for NSCLC.

View Figures

View References

1	Kumar M, Ernani V and Owonikoko TK: Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer. Mol Aspects Med. 45:55–66. 2015. View Article : Google Scholar : PubMed/NCBI
2	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
3	Bilfinger T, Keresztes R, Albano D and Nemesure B: Five-year survival among Stage IIIA lung cancer patients receiving two different treatment modalities. Med Sci Monit. 22:2589–2594. 2016. View Article : Google Scholar : PubMed/NCBI
4	Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P, Mitchell A, Bolejack V, et al: The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 11:39–51. 2016. View Article : Google Scholar : PubMed/NCBI
5	Marra A, Richardsen G, Wagner W, Muller-Tidow C, Koch OM and Hillejan L: Prognostic factors of resected node-positive lung cancer: Location, extent of nodal metastases, and multimodal treatment. Thorac Surg Sci. 8:Doc012011.PubMed/NCBI
6	Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D'Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, et al: Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 15:504–535. 2017. View Article : Google Scholar : PubMed/NCBI
7	Yu SL, Koo H, Lee SI, Kang J, Han YH, Yeom YI and Lee DC: A synthetic CPP33-conjugated HOXA9 active domain peptide inhibits invasion ability of non-small lung cancer cells. Biomolecules. 10:15892020. View Article : Google Scholar
8	Mielgo-Rubio X, Calvo V, Luna J, Remon J, Martín M, Berraondo P, Jarabo JR, Higuera O, Conde E, De Castro J, et al: Immunotherapy moves to the early-stage setting in non-small cell lung cancer: Emerging evidence and the role of biomarkers. Cancers (Basel). 12:34592020. View Article : Google Scholar
9	Mustachio LM and Roszik J: Current targeted therapies for the fight against non-small cell lung cancer. Pharmaceuticals (Basel). 13:3742020. View Article : Google Scholar
10	Mohr AM and Mott JL: Overview of microRNA biology. Semin Liver Dis. 35:3–11. 2015. View Article : Google Scholar : PubMed/NCBI
11	Lu TX and Rothenberg ME: MicroRNA. J Allergy Clin Immunol. 141:1202–1207. 2018. View Article : Google Scholar : PubMed/NCBI
12	Rupaimoole R and Slack FJ: MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
13	Romano G, Veneziano D, Acunzo M and Croce CM: Small non-coding RNA and cancer. Carcinogenesis. 38:485–491. 2017. View Article : Google Scholar : PubMed/NCBI
14	Peng X, Yan B and Shen Y: MiR-1301-3p inhibits human breast cancer cell proliferation by regulating cell cycle progression and apoptosis through directly targeting ICT1. Breast Cancer. 25:742–752. 2018. View Article : Google Scholar : PubMed/NCBI
15	Song XL, Huang B, Zhou BW, Wang C, Liao ZW, Yu Y and Zhao SC: miR-1301-3p promotes prostate cancer stem cell expansion by targeting SFRP1 and GSK3β. Biomed Pharmacother. 99:369–374. 2018. View Article : Google Scholar : PubMed/NCBI
16	Wang L, Zhao Y, Xu M, Zhou F and Yan J: Serum miR-1301-3p, miR-335-5p, miR-28-5p, and their target B7-H3 may serve as novel biomarkers for colorectal cancer. J BUON. 24:1120–1127. 2019.PubMed/NCBI
17	Zhang YQ, Wang WY, Xue JX, Xu Y, Fan P, Caughey BA, Tan WW, Cao GQ, Jiang LL, Lu Y, et al: MicroRNA expression profile on solid subtype of invasive lung adenocarcinoma reveals a panel of four miRNAs to Be associated with poor prognosis in Chinese patients. J Cancer. 7:1610–1620. 2016. View Article : Google Scholar : PubMed/NCBI
18	Huston SF, Abdelmalik AG, Nguyen NC, Farghaly HR and Osman MM: Whole-body 18F-FDG PET/CT: The need for a standardized field of view-a referring-physician aid. J Nucl Med Technol. 38:123–127. 2010. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Pao W and Chmielecki J: Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer. 10:760–774. 2010. View Article : Google Scholar : PubMed/NCBI
21	Ahn YH and Ko YH: Diagnostic and therapeutic implications of microRNAs in non-small cell lung cancer. Int J Mol Sci. 21:87822020. View Article : Google Scholar
22	El Aamri M, Yammouri G, Mohammadi H, Amine A and Korri-Youssoufi H: Electrochemical biosensors for detection of MicroRNA as a cancer biomarker: Pros and Cons. Biosensors. 10:1862020. View Article : Google Scholar
23	Ortiz-Quintero B: Extracellular MicroRNAs as intercellular mediators and noninvasive biomarkers of cancer. Cancers (Basel). 12:34552020. View Article : Google Scholar
24	Wang J, Liu L, Sun Y, Xue Y, Qu J, Pan S, Li H, Qu H, Wang J and Zhang J: miR-615-3p promotes proliferation and migration and inhibits apoptosis through its potential target CELF2 in gastric cancer. Biomed Pharmacother. 101:406–413. 2018. View Article : Google Scholar : PubMed/NCBI
25	Cui HW, Han WY, Hou LN, Yang L, Li X and Su XL: miR-1915-3p inhibits Bcl-2 expression in the development of gastric cancer. Biosci Rep. 39:BSR201823212019. View Article : Google Scholar : PubMed/NCBI
26	Wei Y, Wang Y, Zang A, Wang Z, Fang G and Hong D: miR-4766-5p inhibits the development and progression of gastric cancer by targeting NKAP. Onco Targets Ther. 12:8525–8536. 2019. View Article : Google Scholar : PubMed/NCBI
27	Wei CH, Wu G, Cai Q, Gao XC, Tong F, Zhou R, Zhang RG, Dong JH, Hu Y and Dong XR: MicroRNA-330-3p promotes cell invasion and metastasis in non-small cell lung cancer through GRIA3 by activating MAPK/ERK signaling pathway. J Hematol Oncol. 10:1252017. View Article : Google Scholar : PubMed/NCBI
28	Jia Y, Tan W and Zhou Y: Transfer RNA-derived small RNAs: Potential applications as novel biomarkers for disease diagnosis and prognosis. Ann Transl Med. 8:10922020. View Article : Google Scholar : PubMed/NCBI
29	Parizi PK, Yarahmadi F, Tabar HM, Hosseini Z, Sarli A, Kia N, Tafazoli A and Esmaeili SA: MicroRNAs and target molecules in bladder cancer. Med Oncol. 37:1182020. View Article : Google Scholar : PubMed/NCBI
30	Li K, Xu Y and Yuan LN: Down-regulation of miR-5702 is associated with clinical progression and poor prognosis in patients with non-small-cell lung cancer. Eur Rev Med Pharmacol Sci. 23:2047–2052. 2019.PubMed/NCBI
31	Wang N and Liu W: Increased expression of miR-552 acts as a potential predictor biomarker for poor prognosis of colorectal cancer. Eur Rev Med Pharmacol Sci. 22:412–416. 2018.PubMed/NCBI
32	Wen J, Wang H, Dong T, Gan P, Fang H, Wu S, Li J, Zhang Y, Du R and Zhu Q: STAT3-induced upregulation of lncRNA ABHD11-AS1 promotes tumour progression in papillary thyroid carcinoma by regulating miR-1301-3p/STAT3 axis and PI3K/AKT signalling pathway. Cell Prolif. 52:e125692019. View Article : Google Scholar : PubMed/NCBI
33	Xu G, Wang H, Yuan D, Yao J, Meng L, Li K, Zhang Y, Dang C and Zhu K: RUNX1-activated upregulation of lncRNA RNCR3 promotes cell proliferation, invasion, and suppresses apoptosis in colorectal cancer via miR-1301-3p/AKT1 axis in vitro and in vivo. Clin Transl Oncol. 22:1762–1777. 2020. View Article : Google Scholar : PubMed/NCBI
34	Rege TA and Hagood JS: Thy-1 as a regulator of cell-cell and cell-matrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis. FASEB J. 20:1045–1054. 2006. View Article : Google Scholar : PubMed/NCBI
35	Shentu TP, Huang TS, Cernelc-Kohan M, Chan J, Wong SS, Espinoza CR, Tan C, Gramaglia I, van der Heyde H, Chien S and Hagood JS: Thy-1 dependent uptake of mesenchymal stem cell-derived extracellular vesicles blocks myofibroblastic differentiation. Sci Rep. 7:180522017. View Article : Google Scholar : PubMed/NCBI
36	Schliekelman MJ, Creighton CJ, Baird BN, Chen Y, Banerjee P, Bota-Rabassedas N, Ahn YH, Roybal JD, Chen F, Zhang Y, et al: Thy-1⁺ Cancer-associated fibroblasts adversely impact lung cancer prognosis. Sci Rep. 7:64782017. View Article : Google Scholar : PubMed/NCBI
37	Schubert K, Gutknecht D, Koberle M, Anderegg U and Saalbach A: Melanoma cells use Thy-1 (CD90) on endothelial cells for metastasis formation. Am J Pathol. 182:266–276. 2013. View Article : Google Scholar : PubMed/NCBI
38	Hsu HH, Ko KH, Chou YC, Lin LF, Tsai WC, Lee SC, Chang H and Huang TW: SUVmax and tumor size predict surgical outcome of synchronous multiple primary lung cancers. Medicine (Baltimore). 95:e23512016. View Article : Google Scholar : PubMed/NCBI
39	Petrovic M, Baskic D, Bankovic D and Ilic N: Neuroendocrine differentiation as an indicator of chemosensitivity and prognosis in nonsmall cell lung cancer. Biomarkers. 16:311–320. 2011. View Article : Google Scholar : PubMed/NCBI
40	Fukui M, Suzuki K, Matsunaga T, Oh S and Takamochi K: Importance of smoking cessation on surgical outcome in primary lung cancer. Ann Thorac Surg. 107:1005–1009. 2019. View Article : Google Scholar : PubMed/NCBI